BSE Live
Jan 23, 16:01Prev. Close
1995.90
Open Price
1996.00
Bid Price (Qty.)
1965.65 (2)
Offer Price (Qty.)
1990.00 (5)
NSE Live
Jan 23, 15:43Prev. Close
1997.20
Open Price
2000.00
Bid Price (Qty.)
1967.70 (22)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of Glenmark Pharma (in Rs. Cr.) | Mar 10 | Mar 09 | Mar 08 | Mar 07 | Mar 06 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 121.01 | 246.07 | 431.19 | 170.82 | 85.30 | |
| Net CashFlow From Operating Activities | 983.16 | 94.06 | 246.67 | -8.83 | -25.49 | |
| Net Cash Used In Investing Activities | -1,000.22 | -589.14 | -15.70 | -237.92 | -239.08 | |
| Net Cash Used From Financing Activities | 10.45 | 495.62 | -231.18 | 168.98 | 244.45 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | -6.61 | 0.53 | -0.21 | -77.77 | -20.12 | |
| Cash And Cash Equivalents Begin of Year | 11.69 | 11.16 | 11.39 | 89.16 | 109.28 | |
| Cash And Cash Equivalents End Of Year | 5.08 | 11.69 | 11.18 | 11.39 | 89.16 |
04.12.2025
Glenmark Consolidated September 2025 Net Sales at Rs 6,046.87 crore, up 76.1% Y-o-Y
24.11.2025
Glenmark Standalone September 2025 Net Sales at Rs 1,538.66 crore, down 41.63% Y-o-Y
27.05.2025
Glenmark Standalone March 2025 Net Sales at Rs 2,009.49 crore, down 6.46% Y-o-Y
04.03.2025
Glenmark Consolidated December 2024 Net Sales at Rs 3,387.55 crore, up 35.14% Y-o-Y
08.07.2022
Glenmark Pharmaceuticals Q1 PAT may dip 41.8% YoY to Rs 178.4 cr: Prabhudas Lilladher
14.04.2022
Glenmark Pharmaceuticals Q4 PAT may dip 20.1% YoY to Rs 186.8 cr: Prabhudas Lilladher
13.01.2022
Glenmark Pharmaceuticals Q3 PAT seen up 17.8% YoY to Rs 292.4 cr: Prabhudas Lilladher
06.10.2021
Glenmark Pharmaceuticals Q2 PAT seen up 18.4% YoY to Rs 269.5 cr: Prabhudas Lilladher
31.05.2019
Glenmark Pharma wilts 3% on muted Q4 show, CLSA downgrades to sell
09.02.2018
Glenmark Pharma tanks 9% after disappointing Q3 earnings, US pricing pressure to continue
28.07.2017
31.07.2015